Skip to main content
Fig. 4 | BMC Pulmonary Medicine

Fig. 4

From: Temperature-controlled Laminar Airflow (TLA) in symptomatic severe asthma – a post hoc analysis of severe exacerbations, quality of life and health economics

Fig. 4

Cost-effectiveness grid over the incremental cost-effectiveness ratio (ICER) estimates for TLA from the ACQ7 > 3 sub-group. The utility scores for TLA at 9 and 12 months are shown on the Delta QALY-axis. In addition, the TLA price is shown on the Delta cost-axis resulting in cost-effectiveness (ICER) for TLA of about £17,000–£22,000 (black rectangle), which is below the acceptable recommended threshold for NICE, i.e., <£30,000

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us